A2R and Ectonucleotidases Expression in Lung Cancer Circulating Tumor Cells

NCT ID: NCT05648188

Last Updated: 2025-04-10

Basic Information

• Recruitment Status: WITHDRAWN
• Study Classification: OBSERVATIONAL
• Study Start Date: 2023-01-01
• Study Completion Date: 2024-10-30

Brief Summary

Early non-small cell lung cancer (NSCLC), treated by surgery or radiotherapy in the case of inoperability, relapses in almost 50% of cases. Circulating tumour cells (CTCs), which can be detected before surgery, represent a promising prognostic tool, but the markers characterising their aggressiveness remain to be determined. The NSCLC microenvironment, in which purinergic signalling is a key pathway, controls tumour development. Adenosine derived from the action of CD39 and CD73 ectonucleotidases hydrolysing extracellular ATP, induces immunosuppression of NSCLC by activating A2R receptors. The expression and prognostic relevance of A2R, CD39 and CD73 on CTCs is unknown. The objectives are to (i) compare the expression of A2R and CD39 and CD73 on primary tumour cells and CTCs of patients operated on for early NSCLC, (ii) correlate these data with molecular characteristics and clinical response, (iii) determine on lung cancer lines whether irradiation impacts on the expression of A2R, CD39 and CD73. This work could contribute to the identification of new theranostic biomarkers.

Conditions

Non Small Cell Lung Cancer

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Study Groups

NSCLC patients

Patients with proven stage IA-IIB non-small cell lung cancer (NSCLC).

Sample

Intervention Type: BIOLOGICAL

Sample of whole blood and tissue for ex vivo expression of A2R, CD39, CD73 and P2RX7

Interventions

Sample

Sample of whole blood and tissue for ex vivo expression of A2R, CD39, CD73 and P2RX7

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

• Patient of legal age (>18 years), any gender,
• operated on for stage (IA to IIB) non-small cell lung cancer (NSCLC)

Exclusion Criteria

• Patient with any other active cancer.
• Lack of evaluable material.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Centre Hospitalier Universitaire de Nice

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Jonathan BENZAQUEN, Dr

Role: PRINCIPAL_INVESTIGATOR

Centre Hospitalier Universitaire de Nice

Locations

CHU de Nice

Nice, , France

Countries

France

Other Identifiers

22Pneumo01

Identifier Type: -

Identifier Source: org_study_id